Next Generation Drug Conjugates Market Report 2026

The next generation drug conjugates market size has grown rapidly in recent years. It will grow from $2.47 billion in 2025 to $2.85 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to limitations of conventional chemotherapy, advancements in biologics research, increased cancer prevalence, growth of specialty pharma companies, clinical success of early drug conjugates.

The next generation drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $5.1 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to expansion of personalized medicine, growing oncology drug pipelines, innovation in linker and payload chemistry, rising r&d investments, increasing regulatory approvals. Major trends in the forecast period include rising adoption of targeted drug delivery systems, increasing focus on precision oncology therapies, expansion of advanced payload technologies, growing clinical use of conjugated therapeutics, higher demand for safer high-efficacy drugs.

The increasing incidence of cancer is anticipated to fuel the expansion of the next-generation drug conjugates market in the future. Cancer encompasses a range of diseases marked by the uncontrolled proliferation and dissemination of abnormal cells throughout the body. This surge in cancer cases stems mainly from an aging population, lifestyle choices, environmental influences, better diagnostic methods, genetic predispositions, and infectious causes. Next-generation drug conjugates address cancer by transporting targeted treatments straight to tumor cells, boosting therapeutic effectiveness and reducing harm to normal tissues. For instance, in February 2025, Cancer Australia - a government agency in Australia - reported 4,641 new pancreatic cancer diagnoses in 2024, including 2,414 in males and 2,227 in females, up from 3,968 cases the previous year. Thus, the growing burden of cancer is propelling the next-generation drug conjugates market forward.

Major companies in the next-generation drug conjugates market are pursuing strategic partnerships to boost their research and development capabilities, speed up product innovation, and grow their market presence. Strategic partnerships involve companies combining their strengths and resources to gain mutual benefits and achieve success. For example, in November 2023, Prelude Therapeutics Incorporated, a US-based clinical-stage precision oncology company, collaborated with AbCellera Biologics Inc., a Canada-based biotechnology company, to create first-in-class precision antibody-drug conjugates (ADCs) for oncology. The collaboration focuses on discovering, developing, and commercializing novel antibody-drug conjugates (ADCs), beginning with a program that pairs a SMARCA degrader with a novel antibody. This approach seeks to extend the therapeutic potential of Prelude's small-molecule SMARCA2 selective degraders to a larger patient population, particularly those with cancers not linked to SMARCA4 mutations.

In March 2024, Johnson & Johnson - a U.S.-based producer of pharmaceuticals and medical devices - purchased Ambrx Biopharma for $2 billion. This acquisition seeks to bolster Johnson & Johnson's oncology offerings and accelerate progress on next-generation antibody drug conjugates designed to revolutionize cancer care. Ambrx Biopharma, a U.S.-based clinical-stage biopharmaceutical firm, specializes in next-generation drug conjugates.

Major companies operating in the next generation drug conjugates market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH.

North America was the largest region in the next generation drug conjugates market in 2025. The regions covered in the next generation drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next generation drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs for imported cytotoxic payloads, linker technologies, and advanced manufacturing equipment used in the next generation drug conjugates market. These impacts are most significant in North America and Europe, where complex biopharmaceutical production depends on specialized global suppliers. Rising tariff related expenses have increased development and manufacturing costs for antibody drug conjugates and related therapies. This has influenced investment prioritization and capacity planning among biopharmaceutical companies. However, tariffs are also driving localization of high value biopharmaceutical manufacturing, expanded in region capabilities, and stronger control over critical production technologies.

The next generation drug conjugates market research report is one of a series of new reports that provides next generation drug conjugates market statistics, including next generation drug conjugates industry global market size, regional shares, competitors with a next generation drug conjugates market share, detailed next generation drug conjugates market segments, market trends and opportunities, and any further data you may need to thrive in the next generation drug conjugates industry. This next generation drug conjugates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Next-generation drug conjugates are advanced formulations of drug conjugates engineered to boost the efficacy and safety of targeted therapies. They employ cutting-edge targeting technologies and superior payloads to deliver powerful treatments straight to diseased cells with improved precision and fewer side effects.

The primary categories of next-generation drug conjugates include peptide receptor radionuclide therapy, ligand-mediated RNAi conjugates, ligand-conjugated antisense medicines, and peptide drug conjugates. Peptide Receptor Radionuclide Therapy (PRRT) represents a targeted cancer treatment that employs radioactive peptides to attach to and eliminate tumor cells displaying specific receptors. Targeting ligands encompass amino sugars, lipids, peptides, small molecules, and virus-like particles, while payload types consist of oligonucleotides, radionuclides, peptides, and small molecules. This therapy may be delivered as monotherapy or combination therapy for diverse indications, such as gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis from breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, and more.

The next-generation drug conjugates market consists of revenues earned by entities by providing services such as targeted cancer therapies, gene therapy conjugates, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation drug conjugates market also includes sales of small molecule drug conjugates, RNA-targeted conjugates, and enzyme-linked drug conjugates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.